The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I. Silverberg, Jonathan Zalevsky, David Rosmarin et al.|Nature Communications|2024Cited by 37
Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in RodentsCaroline Machado Kopruszinski, Frank Porreca, Yeon Sun Lee et al.|Cellular and Molecular Neurobiology|2020Cited by 10
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Joseph P. McGuirk, John F. DiPersio et al.|Blood|2024Cited by 3
729 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitisMelinda Gooderham, David Rosmarin, Charles Lynde et al.|British Journal of Dermatology|2024Cited by 2
NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphomaSairah Ahmed, Joseph P. McGuirk, John F. DiPersio et al.|Blood Advances|2025Cited by 1